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Functional imaging studies have suggested that carriers of the apolipoprotein E (APOE) 4 risk allele for Alzheimer’s disease (AD) present with higher levels of neural activity during cognitive tasks (Bookheimer & Burggren, 2009). The association of higher activity for APOE 4 in task dependent areas has been independently replicated in older samples (Bondi, Houston, Eyler, & Brown, 2005; Seidenberg et al., 2009; Smith et al., 2011; Wierenga et al., 2010) It is widely regarded that the higher activation reflects recruitment of more neuronal resources in risk allele carriers to engage with the task (Bondi et al., 2005), possibly to compensate for early preclinical changes in the neurobiology of memory-related areas (Prvulovic et al., 2005). 
	However, APOE is not the only apolipoprotein gene implicated in AD. Recent GWAS (Genome Wide Association Studies) have identified and replicated a risk locus (rs11136000) on the CLU (APOJ) gene (Bertram & Tanzi, 2009; Carrasquillo et al., 2010; Corneveaux et al., 2010; Harold et al., 2009; Lambert et al., 2009). Although clusterin has been implicated in the pathophysiology of AD (Bertram & Tanzi, 2010), little is known about how the gene and its protein product contribute to the manifestation of the disease. CLU levels have previously been correlated with symptom severity, entorhinal/hippocampal cortex atrophy and amyloid-beta (A) burden (Thambisetty et al., 2010). Imaging studies have also demonstrated that the risk locus is associated with variations in cortical morphology (Biffi et al., 2010). However, the functional differences between individuals with risk and protective genotypes have not yet been studied in pre-clinical cases. 














We studied 43 healthy subjects (age range 18-51, median age 29.1, 22 males, 21 females, 3 left handed, 40 right handed). All subjects were of Caucasian ethnicity because ethnic matching is critical in genetic imaging and association studies (Hariri & Weinberger, 2003). Participants and relatives had no history of neuropsychiatric, neurological or neurodegenerative disease. Participants also had no chronic somatic illness or history of substance abuse. Subjects were tested using a robust face working memory paradigm for functional magnetic resonance imaging (fMRI) as previously described (see supplementary material). Data were from a subsample of the participants of a larger genetic imaging study (Wolf et al., 2010), for whom information about the CLU SNP data was available. Subjects were genotyped for CLU rs11136000 (CC: 13, CT: 24, TT=6) and pooled according to hypothesised risk allele (Risk Carriers: CC, Non- Risk CT/TT (Harold et al, 2009). Hardy-Weinberg-Equilibrium was checked with χ2- test (α-level .05; DF = 2) and independent-samples t-test (2-tailed) determined no significant differences in gender (p=.212) and age (p=.174) between risk and protective groups. We acquired fMRI data (T2* weighted echo planar imaging sequence; TR = 2000 ms; TE = 40 ms; matrix size = 96 × 96; FOV =256 × 256 mm2; voxel size =3 × 3 × 3 mm3; 90° flip angle; 20 axial slices; 5 mm slice thickness) on a 1.5 Tesla Philips whole-body MR scanner. 

We estimated activation levels for correct trials of each of the 12 conditions (3 emotions (happy, neutral & angry) x 4 WM loads) using a random effects general linear model (GLM) of the experiment. One separate predictor modeled all error trials, and 6 motion confounds were derived from the head motion correction for each subject. All but the motion predictors were convolved with a two-gamma haemodynamic reference function. Genotype (risk/non risk) was used as a between subjects factor.




























Table 2. Significant main effects of genotype in all 3 regions with addictive, dose-dependent effects of genotype in rDLPFC and rHF. Pair-wise comparisons suggest significant difference in neural activity increases in a dose-dependent manner. (*, p <.05, **, p <.01).

A main effect of genotype, reflecting higher activation for the risk group, was 
observed in the right dorso-lateral prefrontal cortex (rDLPFC) (F1A), the right 
hippocampus/entorhinal cortex (hippocampal formation, rHF) (F1B) and the dorsal Posterior Cingulate (dPC) (F1C) (cluster threshold of 1000 voxels). All three clusters also survived a threshold p< .01 (cluster threshold of 100 voxels), but not a more conservative threshold of p<.001.
The rDLPFC (F1a) and dPC (F1c) showed an interaction between genotype and load in which increased brain activity in the risk group was particularly marked under high memory load (loads 3 and 4). We therefore also performed t-tests for whole brain group differences at just the higher loads (WM loads 3 & 4). For areas demonstrating a significant genotype x load interaction at higher loads (rDLPFC & dPC) clusters demonstrated a more pronounced effect with higher significance (Table 1a & c). There were no differences in the magnitude of genotype main effect between all four WM loads and High WM loads in the rHF, supported by the absence of a genotype X load interaction (Table 1b). 

These effects were further corroborated by a dose dependent rs11136000 













Healthy individuals with the AD risk genotype on the CLU gene activated several brain areas (DLPFC, hippocampus, cingulate) that were not active in the controls. Their performance on the WM task equaled that of controls, and one interpretation is thus that the carriers of the protective allele performed the task with more efficient use of neural resources. Correlations between AD risk (APOE isoform status) and neural hyperactivation have previously been reported in the right dorsolateral prefrontal cortex (Wishart et al, 2006) and hippocampus (Bookheimer et al, 2000).
	This finding of functional changes in young healthy individuals who may have a slightly increased risk of developing AD would conform to neuropathological models where cellular changes of AD can precede the clinical phenotype by several decades (Donev et al, 2009). It is of note that the hyperactive areas included some of those implicated relatively early in the cascade of AD pathology such as HF and PC (Braak & Braak, 1998). This hyperactivation conforms to pathophysiological models of AD vulnerability which posit an initial left-shift of brain activation in response to cognitive demand, resulting in higher activation during early stages of AD pathology and for difficult tasks, followed by hypoactivation once compensation mechanisms have collapsed and the disease manifests itself clinically (Prvulovic et al, 2005). 
	In keeping with this model, the hyperactivation of risk carriers in DLPFC and cingulate was more marked at memory loads 3 and 4 than 1 and 2. These loads were supra-capacity because the limit for face WM is commonly thought to be at two faces (Jackson et al., 2009). 
	What then are the mechanisms through which the risk genotype may lead to compensatory hyper-activation? It could be argued that as CLU belongs to the same protein family as APOE that it may have similar pathophysiological effects, which may explain the similar presentation of compensatory neuronal resources. CLU encodes an extracellular multifunctional glycoprotein that may interact with itself, amyloid proteins and lipids, as well as assisting in synapse turnover (Bertram & Tanzi, 2009) in a similar manner to APOE. It has a potential role in the pathogenesis of AD including the hallmark features of A deposition, aggregation and fibrillogenesis (Bertram & Tanzi, 2009). The cellular mechanisms of neural hyperactivation in carriers of AD risk genes are unknown. The exaggerated calcium signalling observed in association with several AD risk genes and implicated in AD neuropathology (Cowburn et al, 2007; Cheung et al, 2008; Small DH, 2009) may be a factor, but further work on the cellular biology of the CLU risk variant is needed to pursue such a hypothesis. Another possibility is that AD risk is associated with dysregulation of neurovascular coupling, as has been suggested for clinical AD (Girouard and Iadecola, 2006).
	The genetic mechanism underlying the association between the specific variant (rs11136000) and AD also remains unknown. It is possible that rs11136000 directly influences gene expression or splicing, that it is in linkage disequilibrium with another variant that does, or that risk is conferred by some other mechanism. However it seems clear from our data that whatever mechanism is involved, impacts on brain function occur many years before the onset of dementia and can be detected by subtle effects on activation in fMRI experiments. 
	A limitation of the present study was the sample size, although it was within the standard range for current genetic imaging studies (Rasch et al, 2010). Furthermore, although effects were significant at a cluster-level thresholded level of p<.05, they did not withstand more rigorous corrections for multiple comparisons, which calls for replication in larger samples. 
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